283 related articles for article (PubMed ID: 34367963)
1. RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma.
Liu B; Wang Y; Wang H; Li Z; Yang L; Yan S; Yang X; Ma Y; Gao X; Guan Y; Yi X; Xia X; Li J; Wu N
Front Oncol; 2021; 11():677826. PubMed ID: 34367963
[TBL] [Abstract][Full Text] [Related]
2. Investigation of
Cao Y; Lan D; Ke X; Zheng W; Zeng J; Niu N; Fu C; Deng W; Jin S
Heliyon; 2024 Jun; 10(11):e32287. PubMed ID: 38912481
[TBL] [Abstract][Full Text] [Related]
3. RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H.
Zhang S; Bao Y; Shen X; Pan Y; Sun Y; Xiao M; Chen K; Wei H; Zuo J; Saffen D; Zong WX; Sun Y; Wang Z; Wang Y
EBioMedicine; 2020 Nov; 61():103067. PubMed ID: 33130397
[TBL] [Abstract][Full Text] [Related]
4. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
He Z; Feng W; Wang Y; Shi L; Gong Y; Shi Y; Shen S; Huang H
Transl Lung Cancer Res; 2023 Mar; 12(3):510-529. PubMed ID: 37057124
[TBL] [Abstract][Full Text] [Related]
5. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
6. Identification of CNKSR1 as a biomarker for "cold" tumor microenvironment in lung adenocarcinoma: An integrative analysis based on a novel workflow.
Cai Q; Peng M
Heliyon; 2024 Apr; 10(8):e29126. PubMed ID: 38628722
[TBL] [Abstract][Full Text] [Related]
7. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
8. Association of
Jia M; Yao L; Yang Q; Chi T
Front Oncol; 2020; 10():168. PubMed ID: 32154170
[TBL] [Abstract][Full Text] [Related]
9. RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition.
Bao Y; Zhang S; Zhang X; Pan Y; Yan Y; Wang N; Ren Y; Zuo J; Zong WX; Wang Z; Wang Y
Cancer Res; 2023 May; 83(9):1490-1502. PubMed ID: 36853175
[TBL] [Abstract][Full Text] [Related]
10. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD).
Wu L; Liu Q; Ruan X; Luan X; Zhong Y; Liu J; Yan J; Li X
Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509501
[TBL] [Abstract][Full Text] [Related]
11. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
[TBL] [Abstract][Full Text] [Related]
12. Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma.
Li Z; Wang W; Wu J; Ye X
Front Med (Lausanne); 2022; 9():962972. PubMed ID: 36091687
[TBL] [Abstract][Full Text] [Related]
13. Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.
Li X; Zhai S; Zhang J; Zhang D; Wang S; Wang L; Yu J
Front Oncol; 2021; 11():698465. PubMed ID: 34195096
[TBL] [Abstract][Full Text] [Related]
14. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing.
Zhao J; Sun Y; Huang Y; Song F; Huang Z; Bao Y; Zuo J; Saffen D; Shao Z; Liu W; Wang Y
Sci Rep; 2017 Jan; 7():40488. PubMed ID: 28091594
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors.
Niu Y; Lin A; Luo P; Zhu W; Wei T; Tang R; Guo L; Zhang J
Front Pharmacol; 2020; 11():1213. PubMed ID: 32903385
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of Immune Implication and Prognostic Value of
Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
Front Oncol; 2021; 11():798425. PubMed ID: 35047409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
